Stay updated on PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Sign up to get notified when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.

Latest updates to the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check18 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check25 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check61 days agoChange DetectedThe webpage has been updated to reflect a new phase II study focusing on the combination of PEGPH20 and pembrolizumab for advanced pancreatic cancer patients with HA-high expression. Key collaborators and the principal investigator have been specified, and the revision number has been updated.SummaryDifference49%
Stay in the know with updates to PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.